Document is current
Any future updates will be listed below
-
Authors
Lynch, Shannon E.
Alsheikh, Heba M.
Song, Patrick N.
Parker, Candace C.
Zhang, Yujun
Yates, Clayton C.
Larimer, Benjamin M.
Lapi, Suzanne E.
Shevde, Lalita A.
Sorace, Anna G. https://orcid.org/0000-0002-3640-3966
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA240589)
National Cancer Institute (R01CA276540)
National Cancer Institute (R01CA262160)
National Cancer Institute (DP2CA261453)
National Institute of General Medical Sciences (T32GM135028)
Foundation for the National Institutes of Health (P30CA013148)
- License Information
-
More Information
Article History
Received: 30 April 2025
Revised: 3 June 2025
Accepted: 9 June 2025
First Online: 12 August 2025
Declarations
:
: B.M.L. is the co-founder and CEO of CytoSite Biopharma. C.Y. is a shareholder in Riptide Biosciences. C.Y. is a Riptide Biosciences and PreludeDX consultant and has received Honoria fees from Amgen and Regeneron
